AThe big banks are split down the middle on how hot October inflation ran.
BSplit by a tenth of a percent. Wall Street's most boring knife fight.
AThat tenth decides whether the Fed thinks inflation is stuck or fading.
AFor a decade before the pandemic, core CPI often ran near two-tenths a month. That was normal.
BNow the argument is whether one-tenth or two-tenths means the old normal is back or we're stuck above it.
ABut the market reacts to exactly this one. A cold number and rate-cut bets jump.
BThat's the problem: the market overreacts to an estimate. These are banks that can't forecast their own revenue.
AThey forecast revenue fine. Bonuses, less.
BFair. But you're defending the gap. The posts have Goldman and Morgan Stanley at one-tenth. JPMorgan and Bank of America at two-tenths.
AAnd Noah on X put Goldman's core at sixteen hundredths of a percent. The posts don't even agree with each other.
BWait, so Zabi Bidaar on X has Goldman at one-tenth, and Noah has sixteen hundredths? That's not a clean disagreement, that's model noise.
AExactly. Neither list matches a reliable aggregator I've seen. These are unverified estimates floating around after the month's data was locked.
BSo why are we talking about them?
ABecause real money gets positioned off the first credible forecast or leak. If the true core print is one-tenth, the Fed can say disinflation is back.
BAnd if it's two-tenths, the "last mile" is still hard. I get the game. I just think it's a bad game.
AIt's the only game until the official read lands. We're not predicting the number, we're watching the disagreement.
BFine. But a tenth of a percent on monthly core CPI is within any model's error. You can't trade it.
AYou absolutely can trade it, and people do. The point is the Fed's reaction zone is that tight.
BOh, come on. The Fed has told everyone it's data-dependent, not print-dependent.
AThey say that. Then one cold print and the two-year yield moves ten basis points.
BSo the market is twitchy. We agree. The disagreement over bank forecasts is noise, not signal.
AThe disagreement is the signal. If banks can't settle on one-tenth versus two-tenths, the inflation trend is genuinely unclear.
BI'll give you that. It's unclear, and the banks are guessing.
ASome are modeling. Wells Fargo had headline at twenty-eight basis points in one post; that's a claimed forecast, not a confirmed one.
BA forecast can still be a guess with a tie on. No reliable aggregator, remember?
ATrue. I'm not vouching for any single number. I'm saying the split tells you the usual post-COVID disinflation story is wobbling.
BOr the split tells you the banks' models are all over the place because October had weird seasonal adjustments.
AThat's my point: if it's seasonal noise, the Fed should look through it. If it's trend, they can't.
BAnd they will look through it. Central banks are not day traders.
ATell that to the people pricing rate cuts off these posts.
BI'd rather not. They're busy refreshing.
ASpeaking of banks misreading their own data—
BDifferent corner of the bank world: CAGS on X posted that big banks are still sitting at fifteen to twenty dollars on Iovance Biotherapeutics.
A"Still sitting" is doing a lot of work. The targets are fifteen to twenty, but the consensus average is around fourteen-twenty, not the thirteen-to-fourteen the post claims.
BRight. The big-bank targets are mostly there, but the crowd average is lower.
AAnd after the lung timeline shifted to the precision biomarker cohort they call POSITILITY, the bank targets still span fifteen to twenty.
BThe post has Goldman at fifteen, Jefferies at twenty. That's a wide range for a clinical-stage biotech.
AWide because the outcome is binary. If the biomarker cohort works, these targets are low. If it misses, they're fantasy.
BSo the price targets don't tell you anything except where analysts' conviction happens to sit.
AThat's not nothing. But the post made the average look like support, and it isn't.
BConflating a price target with support is how retail gets hurt. A target is a forecast, not a floor.
AExactly. And the real story is that the post says Iovance is pivoting lung cancer to a biomarker-defined group — that's a scientific bet, not a bank target.
BHard to disagree. The science matters more than the range.
AThen we agree. The post's range is mostly right, the average is wrong, and the trial is the thing.
BAnd nobody should read a bank target as a promise. Good note to end on.